Literature DB >> 24169761

Elevated circulating levels of tissue factor-positive microvesicles are associated with distant metastasis in lung cancer.

Jo-Chi Tseng1, Liang-Che Chang, Boy-Yiing Jiang, Yu-Chih Liu, Hung-Jie Chen, Chih-Teng Yu, Chung-Ching Hua.   

Abstract

PURPOSE: Microvesicles (MV) in the blood stream are associated with distant metastasis in cancer. Platelet or endothelial cell-related MV actively participate in thrombogenesis, which is an important step in cancer metastasis. This study investigated the correlations between MV levels of platelet-poor plasma and distant metastasis in lung cancer.
METHODS: Platelet-poor plasma from 44 treatment-naive lung cancer (23 with distant metastasis) and 19 normal subjects was used to determine the levels of glycoprotein Iβ (CD42) + platelet MV (PMV), P-selectin (CD62P) + PMV, VE-cadherin (CD144) + endothelial MV (EMV), tissue factor (CD142) + MV, thrombin-antithrombin complex and vascular endothelial growth factor (VEGF).
RESULTS: The level of CD142 + MV was significant (odds ratio 5.86, 95 % confidence interval 1.31-38.3) in predicting distant metastasis in lung cancer, and a cutoff value of 2.668 (after logarithm transformation) in the ROC curve had a specificity of 90 % and a sensitivity of 59 %. The presence of distant metastasis showed a significant correlation between CD144 + EMV and VEGF, but not between CD144 + EMV and CD42 + PMV or CD62P + PMV in lung cancer subjects.
CONCLUSIONS: The finding of CD142 + MV in platelet-poor plasma may be useful for suggesting distant metastasis in lung cancer. In addition to thrombogenesis, interaction between VE-cadherin and VEGF may be needed for successful metastasis in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24169761     DOI: 10.1007/s00432-013-1544-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

Review 1.  Circulating microparticles: pathophysiology and clinical implications.

Authors:  Andrea Piccin; William G Murphy; Owen P Smith
Journal:  Blood Rev       Date:  2006-11-22       Impact factor: 8.250

2.  Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.

Authors:  Nicolas Amabile; Alain P Guérin; Aurélie Leroyer; Ziad Mallat; Clément Nguyen; Jacques Boddaert; Gérard M London; Alain Tedgui; Chantal M Boulanger
Journal:  J Am Soc Nephrol       Date:  2005-09-28       Impact factor: 10.121

Review 3.  Microvesicles: mediators of extracellular communication during cancer progression.

Authors:  Vandhana Muralidharan-Chari; James W Clancy; Alanna Sedgwick; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2010-05-15       Impact factor: 5.285

Review 4.  Antithrombin III: structural and functional aspects.

Authors:  L Mourey; J P Samama; M Delarue; J Choay; J C Lormeau; M Petitou; D Moras
Journal:  Biochimie       Date:  1990-08       Impact factor: 4.079

Review 5.  Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.

Authors:  Mary Lynn Nierodzik; Simon Karpatkin
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

Review 6.  Cancer and thromboembolic disease: pathogenic mechanisms.

Authors:  Agnes Y Lee
Journal:  Cancer Treat Rev       Date:  2002-06       Impact factor: 12.111

Review 7.  VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation.

Authors:  Dietmar Vestweber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-12-27       Impact factor: 8.311

Review 8.  Beyond vessels: occurrence and regional clustering of vascular endothelial (VE-)cadherin-containing junctions in non-endothelial cells.

Authors:  Judit Boda-Heggemann; Anne Régnier-Vigouroux; Werner W Franke
Journal:  Cell Tissue Res       Date:  2008-11-11       Impact factor: 5.249

Review 9.  Tight junctions in cancer metastasis.

Authors:  Tracey A Martin; Malcolm D Mason; Wen G Jiang
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

10.  Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis.

Authors:  Sara Weis; Jianhua Cui; Leo Barnes; David Cheresh
Journal:  J Cell Biol       Date:  2004-10-25       Impact factor: 10.539

View more
  7 in total

1.  [Tissue factors and venous thromboembolism in cancer patients].

Authors:  Huiqi Zhu; Kejing Ying
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-25

2.  Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles.

Authors:  Lucas Treps; Raul Perret; Sébastien Edmond; Damien Ricard; Julie Gavard
Journal:  J Extracell Vesicles       Date:  2017-08-08

3.  Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.

Authors:  Qing Zhang; Haiyu Wang; Huizhong Li; Jinjing Xu; Kang Tian; Jie Yang; Zheng Lu; Junnian Zheng
Journal:  Oncotarget       Date:  2017-02-07

4.  Longitudinal Dynamics of Coagulation and Angiogenesis Markers in Cancer Patients During and After Chemotherapy.

Authors:  Elina A Beleva; Tanya I Deneva; Snezhana S Stoencheva; Zhanet G Grudeva-Popova
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

5.  Selective Internal Radiotherapy Changes the Immune Profiles of Extracellular Vesicles and Their Immune Origin in Patients with Inoperable Cholangiocarcinoma.

Authors:  Florian Haag; Anjana Manikkam; Daniel Kraft; Caroline Bär; Vanessa Wilke; Aleksander J Nowak; Jessica Bertrand; Jazan Omari; Maciej Pech; Severin Gylstorff; Borna Relja
Journal:  Cells       Date:  2022-07-27       Impact factor: 7.666

Review 6.  Extracellular vesicle profiling and their use as potential disease specific biomarker.

Authors:  Henrike Julich; Arnulf Willms; Veronika Lukacs-Kornek; Miroslaw Kornek
Journal:  Front Immunol       Date:  2014-09-01       Impact factor: 7.561

7.  Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells.

Authors:  Ming-Szu Hung; I-Chuan Chen; Jr-Hau Lung; Paul-Yann Lin; Ya-Chin Li; Ying-Huang Tsai
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.